Jasper appoints Thomas G. Wiggans as Chairperson; William Lis to retire in Dec 2023

Jasper Therapeutics, Inc.

Thomas G. Wiggans joins Board as Class II director and Chairperson effective Nov 1, 2023.
Wiggans, 71, is former CEO/founder of Dermira (acquired by Lilly), ex-CEO of Pardes Biosciences.
Wiggans receives option to purchase 110,000 shares, vesting over 4 years; larger than standard director grant.
William Lis steps down as Chairperson immediately, will resign from Board on Dec 14, 2023 (no disagreement).
Company focuses on briquilimab for mast cell diseases and LR-MDS; initial CSU study launching.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas G. Wiggans

Chairperson of the Board

JSPR · Jasper Therapeutics, Inc.

Effective: 2023-11-01
Filed: November 1, 2023, 7:59 PM ET

Effective November 1, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Thomas G. Wiggans as a Class II director of the Company. Mr. Wiggans was also appointed to serve as Chairperson of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas G. Wiggans was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..

Action: appointed
Role: Chairperson of the Board

Exact text from the filing

Effective November 1, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Thomas G. Wiggans as a Class II director of the Company. Mr. Wiggans was also appointed to serve as Chairperson of the Board.

View on SEC.gov

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-081941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.